Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,48 NOK | +0,37% | -6,48% | +12,76% |
Vakgebied
Aantal werknemers: 8
Verkoop per activiteit
NOK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Oncolytic Peptides
100,0
%
| 17 | 100,0 % | 4 | 100,0 % | -76,89% |
Verkoop per regio
NOK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 11 | 63,9 % | 4 | 100,0 % | -63,82% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 01-01-03 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 01-01-08 | |
Gry Stensrud
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Ole Peter Nordby
IRC | Investor Relations Contact | - | - |
- | - | ||
Stephen Worsley
PRN | Corporate Officer/Principal | 60 | 06-09-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 07-06-21 |
Director/Board Member | 66 | 07-06-21 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 07-06-21 |
Øystein Rekdal
CEO | Chief Executive Officer | - | 01-01-03 |
Marie Roskrow
CHM | Chairman | - | 18-04-23 |
Evelina Vågesjö
BRD | Director/Board Member | 38 | 07-06-21 |
Director/Board Member | 59 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 50 578 121 | 29 872 541 ( 59,06 %) | 0 | 59,06 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Chiffre d''affaires - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,76% | 20,24 mln. | |
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |
- Beurs
- Aandelen
- Koers LYTIX
- Onderneming Lytix Biopharma